Evidence map›Paper›PMID 28624906›Full record

ReviewAnnals of hematology2017

Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Giovanni Di Minno, David Navarro, Carlo Federico Perno, Mariana Canaro, Lutz Gürtler, James W Ironside, Hermann Eichler, Andreas Tiede

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04372979 (Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04372979 phase3terminatednot on this mapstarted 2020, after this paper: background citation

Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.

TypeinterventionalSponsorDirection Centrale du Service de Santé des ArméesRan2020 to 2021Enrolled18ConditionsCOVID-19ArmsTransfusion of SARS-CoV-2 Convalescent Plasma., Transfusion of standard Plasma.
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Platelet Transfusion for Patients with Cancer: An Update.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Review
  2. Review
  3. Review
  4. Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giovanni Di MinnoDipartimento di Medicina Clinica e Chirurgia, Regional Reference Centre for Coagulation Disorders, Federico II University, Via S. Pansini 5, 80131, Naples, Italy. diminno@unina.it.
David NavarroDepartment of Microbiology, Microbiology Service, Hospital Clínico Universitario, School of Medicine, University of Valencia, Valencia, Spain.
Carlo Federico PernoDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Mariana CanaroDepartment of Hemostasis and Thrombosis, Son Espases University Hospital, Palma de Mallorca, Spain.
Lutz GürtlerMax von Pettenkofer Institute for Hygiene and Medical Microbiology, University of München, Munich, Germany.
James W IronsideNational Creutzfeldt-Jakob Disease Research and Surveillance Unit, School of Clinical Sciences, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Hermann EichlerInstitute of Clinical Hemostaseology and Transfusion Medicine, Saarland University Hospital, Homburg, Germany.
Andreas TiedeDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood products has fallen considerably over the past three decades, contamination is still a topic of concern. In order to counsel patients and obtain informed consent before transfusion, physicians are required to keep up to date with current knowledge on residual risk of pathogen transmission and methods of pathogen removal/inactivation. Here, we describe pathogens relevant to transfusion of blood products and discuss contemporary pathogen removal/inactivation procedures, as well as the potential risks associated with these products: the risk of contamination by infectious agents varies according to blood product/region, and there is a fine line between adequate inactivation and functional impairment of the product. The cost implications of implementing pathogen inactivation technology are also considered.

Indexed as

Blood-Borne PathogensBlood Coagulation DisordersBlood SafetyBlood TransfusionDisinfectionHemorrhagic DisordersHumansRisk AssessmentRisk FactorsSepsisBleeding disorderBloodClottingInactivationInfection riskPathogenPatient informationRemovalVirus

Identifiers

PMID28624906
PMCPMC5486800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.